Logo image of FF.MI

FINE FOODS & PHARMACEUTICALS (FF.MI) Stock Fundamental Analysis

Europe - Euronext Milan - BIT:FF - IT0005215329 - Common Stock

9.86 EUR
+0.04 (+0.41%)
Last: 1/16/2026, 7:00:00 PM
Fundamental Rating

6

We assign a fundamental rating of 6 out of 10 to FF. FF was compared to 22 industry peers in the Life Sciences Tools & Services industry. FF has an average financial health and profitability rating. A decent growth rate in combination with a cheap valuation! Better keep an eye on FF. With these ratings, FF could be worth investigating further for value investing!.


Dividend Valuation Growth Profitability Health

6

1. Profitability

1.1 Basic Checks

  • In the past year FF was profitable.
  • In the past year FF had a positive cash flow from operations.
  • In multiple years FF reported negative net income over the last 5 years.
  • FF had a positive operating cash flow in 4 of the past 5 years.
FF.MI Yearly Net Income VS EBIT VS OCF VS FCFFF.MI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M -60M -80M

1.2 Ratios

  • FF's Return On Assets of 6.89% is amongst the best of the industry. FF outperforms 81.82% of its industry peers.
  • FF has a better Return On Equity (13.58%) than 81.82% of its industry peers.
  • FF has a Return On Invested Capital of 9.84%. This is amongst the best in the industry. FF outperforms 81.82% of its industry peers.
  • Measured over the past 3 years, the Average Return On Invested Capital for FF is significantly below the industry average of 9.34%.
  • The 3 year average ROIC (3.16%) for FF is below the current ROIC(9.84%), indicating increased profibility in the last year.
Industry RankSector Rank
ROA 6.89%
ROE 13.58%
ROIC 9.84%
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
FF.MI Yearly ROA, ROE, ROICFF.MI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 5 -5

1.3 Margins

  • The Profit Margin of FF (5.07%) is worse than 68.18% of its industry peers.
  • The Operating Margin of FF (7.85%) is worse than 77.27% of its industry peers.
  • FF's Operating Margin has improved in the last couple of years.
  • FF has a Gross Margin of 34.77%. This is comparable to the rest of the industry: FF outperforms 45.45% of its industry peers.
  • FF's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 7.85%
PM (TTM) 5.07%
GM 34.77%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
FF.MI Yearly Profit, Operating, Gross MarginsFF.MI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10 20 30

5

2. Health

2.1 Basic Checks

  • FF has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • Compared to 1 year ago, FF has about the same amount of shares outstanding.
  • The number of shares outstanding for FF has been increased compared to 5 years ago.
  • The debt/assets ratio for FF has been reduced compared to a year ago.
FF.MI Yearly Shares OutstandingFF.MI Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M
FF.MI Yearly Total Debt VS Total AssetsFF.MI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 100M 200M 300M

2.2 Solvency

  • An Altman-Z score of 3.08 indicates that FF is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 3.08, FF is in line with its industry, outperforming 54.55% of the companies in the same industry.
  • FF has a Debt/Equity ratio of 0.44. This is a healthy value indicating a solid balance between debt and equity.
  • FF has a better Debt to Equity ratio (0.44) than 77.27% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Altman-Z 3.08
ROIC/WACC1.09
WACC9%
FF.MI Yearly LT Debt VS Equity VS FCFFF.MI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

  • A Current Ratio of 1.67 indicates that FF should not have too much problems paying its short term obligations.
  • FF has a better Current ratio (1.67) than 86.36% of its industry peers.
  • A Quick Ratio of 1.07 indicates that FF should not have too much problems paying its short term obligations.
  • Looking at the Quick ratio, with a value of 1.07, FF is in line with its industry, outperforming 50.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.67
Quick Ratio 1.07
FF.MI Yearly Current Assets VS Current LiabilitesFF.MI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M

6

3. Growth

3.1 Past

  • FF shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 147.03%, which is quite impressive.
  • The Revenue has been growing slightly by 1.78% in the past year.
  • Measured over the past years, FF shows a quite strong growth in Revenue. The Revenue has been growing by 8.83% on average per year.
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%

3.2 Future

  • FF is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 27.39% yearly.
  • Based on estimates for the next years, FF will show a quite strong growth in Revenue. The Revenue will grow by 12.10% on average per year.
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FF.MI Yearly Revenue VS EstimatesFF.MI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
FF.MI Yearly EPS VS EstimatesFF.MI Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 0 0.2 -0.2 0.4 0.6 0.8

7

4. Valuation

4.1 Price/Earnings Ratio

  • With a Price/Earnings ratio of 11.08, the valuation of FF can be described as very reasonable.
  • 95.45% of the companies in the same industry are more expensive than FF, based on the Price/Earnings ratio.
  • FF is valuated cheaply when we compare the Price/Earnings ratio to 27.47, which is the current average of the S&P500 Index.
  • Based on the Price/Forward Earnings ratio of 14.04, the valuation of FF can be described as correct.
  • Based on the Price/Forward Earnings ratio, FF is valued cheaply inside the industry as 95.45% of the companies are valued more expensively.
  • When comparing the Price/Forward Earnings ratio of FF to the average of the S&P500 Index (24.26), we can say FF is valued slightly cheaper.
Industry RankSector Rank
PE 11.08
Fwd PE 14.04
FF.MI Price Earnings VS Forward Price EarningsFF.MI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 5 10 15 20 25

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of FF indicates a rather cheap valuation: FF is cheaper than 100.00% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 6.01
FF.MI Per share dataFF.MI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10 15

4.3 Compensation for Growth

  • FF's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
  • FF has a very decent profitability rating, which may justify a higher PE ratio.
  • FF's earnings are expected to grow with 29.85% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.21
PEG (5Y)N/A
EPS Next 2Y36.38%
EPS Next 3Y29.85%

6

5. Dividend

5.1 Amount

  • FF has a Yearly Dividend Yield of 1.50%.
  • FF's Dividend Yield is rather good when compared to the industry average which is at 0.54. FF pays more dividend than 95.45% of the companies in the same industry.
  • FF's Dividend Yield is slightly below the S&P500 average, which is at 1.89.
Industry RankSector Rank
Dividend Yield 1.5%

5.2 History

  • The dividend of FF has a limited annual growth rate of 4.24%.
Dividend Growth(5Y)4.24%
Div Incr Years0
Div Non Decr Years0

5.3 Sustainability

  • 18.40% of the earnings are spent on dividend by FF. This is a low number and sustainable payout ratio.
  • FF's earnings are growing more than its dividend. This makes the dividend growth sustainable.
DP18.4%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
FF.MI Yearly Income VS Free CF VS DividendFF.MI Yearly Income VS Free CF VS DividendYearly Income VS Free CF VS Dividend 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -20M -40M -60M -80M
FF.MI Dividend Payout.FF.MI Dividend Payout, showing the Payout Ratio.FF.MI Dividend Payout.PayoutRetained Earnings

FINE FOODS & PHARMACEUTICALS

BIT:FF (1/16/2026, 7:00:00 PM)

9.86

+0.04 (+0.41%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)11-06
Earnings (Next)03-11
Inst Owners12%
Inst Owner ChangeN/A
Ins Owners53.17%
Ins Owner ChangeN/A
Market Cap217.51M
Revenue(TTM)373.66M
Net Income(TTM)18.62M
Analysts85.45
Price Target12.51 (26.88%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 1.5%
Yearly Dividend0.12
Dividend Growth(5Y)4.24%
DP18.4%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)1.66%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)13.48%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)-1.07%
Valuation
Industry RankSector Rank
PE 11.08
Fwd PE 14.04
P/S 0.59
P/FCF N/A
P/OCF 5.89
P/B 1.59
P/tB 1.76
EV/EBITDA 6.01
EPS(TTM)0.89
EY9.03%
EPS(NY)0.7
Fwd EY7.12%
FCF(TTM)-0.21
FCFYN/A
OCF(TTM)1.67
OCFY16.96%
SpS16.64
BVpS6.22
TBVpS5.62
PEG (NY)0.21
PEG (5Y)N/A
Graham Number11.16
Profitability
Industry RankSector Rank
ROA 6.89%
ROE 13.58%
ROCE 14.28%
ROIC 9.84%
ROICexc 11.04%
ROICexgc 11.92%
OM 7.85%
PM (TTM) 5.07%
GM 34.77%
FCFM N/A
ROA(3y)-0.42%
ROA(5y)0.94%
ROE(3y)-1.24%
ROE(5y)0.96%
ROIC(3y)3.16%
ROIC(5y)3.16%
ROICexc(3y)3.64%
ROICexc(5y)4.57%
ROICexgc(3y)4.02%
ROICexgc(5y)5.02%
ROCE(3y)4.59%
ROCE(5y)4.62%
ROICexgc growth 3Y13.05%
ROICexgc growth 5Y-1.19%
ROICexc growth 3Y17.44%
ROICexc growth 5Y-2.63%
OM growth 3Y24.97%
OM growth 5Y2.12%
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y4.32%
GM growth 5Y2.27%
F-Score7
Asset Turnover1.36
Health
Industry RankSector Rank
Debt/Equity 0.44
Debt/FCF N/A
Debt/EBITDA 1.35
Cap/Depr 262.56%
Cap/Sales 11.33%
Interest Coverage 250
Cash Conversion 82.61%
Profit Quality N/A
Current Ratio 1.67
Quick Ratio 1.07
Altman-Z 3.08
F-Score7
WACC9%
ROIC/WACC1.09
Cap/Depr(3y)145.26%
Cap/Depr(5y)138.08%
Cap/Sales(3y)9.82%
Cap/Sales(5y)9.37%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)147.03%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3.62%
EPS Next Y53.89%
EPS Next 2Y36.38%
EPS Next 3Y29.85%
EPS Next 5Y27.39%
Revenue 1Y (TTM)1.78%
Revenue growth 3Y7.75%
Revenue growth 5Y8.83%
Sales Q2Q%12.18%
Revenue Next Year5.61%
Revenue Next 2Y9.55%
Revenue Next 3Y9.52%
Revenue Next 5Y12.1%
EBIT growth 1Y70.93%
EBIT growth 3Y34.65%
EBIT growth 5Y11.14%
EBIT Next Year142.69%
EBIT Next 3Y46.91%
EBIT Next 5Y31.96%
FCF growth 1Y57.35%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y568.5%
OCF growth 3YN/A
OCF growth 5Y19.07%

FINE FOODS & PHARMACEUTICALS / FF.MI FAQ

What is the fundamental rating for FF stock?

ChartMill assigns a fundamental rating of 6 / 10 to FF.MI.


Can you provide the valuation status for FINE FOODS & PHARMACEUTICALS?

ChartMill assigns a valuation rating of 7 / 10 to FINE FOODS & PHARMACEUTICALS (FF.MI). This can be considered as Undervalued.


Can you provide the profitability details for FINE FOODS & PHARMACEUTICALS?

FINE FOODS & PHARMACEUTICALS (FF.MI) has a profitability rating of 6 / 10.


Can you provide the financial health for FF stock?

The financial health rating of FINE FOODS & PHARMACEUTICALS (FF.MI) is 5 / 10.


Can you provide the expected EPS growth for FF stock?

The Earnings per Share (EPS) of FINE FOODS & PHARMACEUTICALS (FF.MI) is expected to grow by 53.89% in the next year.